Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease - Seite 3

---

^[1] Vedolizumab is a monoclonal anti-integrin antibody developed by Millennium Pharmaceuticals.

Succesful completion of regulatory discussions filgotinib in IBD

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire